BioPharmSignal logoBioPharmSignal

Biotech News

CytomX Therapeutics Announces Appointment of Charles Fuchs, M.D., M.P.H., to the Board of Directors

CytomX Therapeutics, Inc. (CTMX)CytomX Therapeutics, Inc.Company update

SOUTH SAN FRANCISCO, Calif., July 27, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced the appointment of Charles Fuchs, M.D., M.P.H., to its Board of Directors. “We are pleased to welcome Dr.

Related news

CTMXCytomX Therapeutics, Inc.2026-08-03 12:00 EST

CytomX Therapeutics Appoints Alejandra Carvajal as Chief Legal Officer

CTMXCytomX Therapeutics, Inc.2026-07-30 12:00 EST

CytomX Therapeutics to Report Second Quarter 2026 Financial Results on August 6, 2026

KYMRKymera2026-06-24 20:01 EST

Kymera Therapeutics Appoints Felix J. Baker, Ph.D., as Chairman of the Board of Directors

FATEFate Therapeutics2026-06-15 12:30 EST

Fate Therapeutics Appoints Laura Hamill to Board of Directors

BNTXBioNTech2026-08-03 09:00 EST

BioNTech Announces Appointment of Guido Oelkers to Management Board as Chief Executive Officer

ELVNEnliven Therapeutics2026-06-15 20:40 EST

Enliven Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional Shares

NRIXNurix Therapeutics2026-08-04 05:00 EST

Nurix Therapeutics Announces First Patient Enrolled in Registrational Phase 3 DAYBreak CLL-306 Trial of Bexobrutideg in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

FATEFate Therapeutics2026-08-03 20:05 EST

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

NRIXNurix Therapeutics2026-07-21 20:01 EST

Nurix Therapeutics Announces HSR Clearance of Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg Across Malignant Hematology, Immunology and Neurology

ELVNEnliven Therapeutics2026-06-12 02:39 EST

Enliven Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants

View all latest news

CytomX Therapeutics, Inc.

Conditionally Activated Biologics CytomX Therapeutics develops masked PROBODY therapeutics designed to become active in the tumor microenvironment. The approach aims to improve the therapeutic window of potent antibodies and antibody-drug conjugates. Varsetatug Masetecan Varsetatug masetecan, or Varseta-M, is an EpCAM-directed PROBODY...

Recent company news

CTMXCytomX Therapeutics, Inc.2026-08-06 20:15 EST

CytomX Therapeutics Announces Q2 2026 Financial Results and Provides Business Update

CTMXCytomX Therapeutics, Inc.2026-08-03 12:00 EST

CytomX Therapeutics Appoints Alejandra Carvajal as Chief Legal Officer

CTMXCytomX Therapeutics, Inc.2026-07-30 12:00 EST

CytomX Therapeutics to Report Second Quarter 2026 Financial Results on August 6, 2026

CTMXCytomX Therapeutics, Inc.2026-07-27 12:00 EST

CytomX Therapeutics Announces Appointment of Charles Fuchs, M.D., M.P.H., to the Board of Directors

CTMXCytomX Therapeutics, Inc.2026-06-03 12:00 EST

CytomX Announces Expansion of Strategic Research Collaboration with Regeneron in the Field of Conditional Bispecific Therapeutics for the Treatment of Cancer

Stock data

Close
3.37 USD
Market cap
687.94M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States